Comparison · NCT02980874-sae
Active vs Control: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Active vs Control: serious adverse events. Trial comparisons, record NCT02980874-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02980874-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.108 | 0.0744 | 0.155 | wilson | |
| Risk in group 2 | 0.122 | 0.086 | 0.171 | wilson | |
| Risk difference, group 1 minus group 2 | -0.014 | -0.0734 | 0.0451 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.885 | 0.533 | 1.47 | log | |
| Odds ratio, group 1 over group 2 | 0.871 | 0.491 | 1.55 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Active than on Control | 71.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Active | IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections~suprachoroidal CLS-TA: suprachoroidal injection of CLS-TA~IVT aflibercept: 2 mg intravitreal injection of aflibercept | 25 | 231 | EG000 |
| Group 2 | Control | IVT aflibercept (2 mg/0.05 mL) + sham SC procedure~suprachoroidal sham: suprachoroidal sham procedure~IVT aflibercept: 2 mg intravitreal injection of aflibercept | 28 | 229 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were collected over 48 weeks of follow-up.
Source ClinicalTrials.gov
Trial
- Title
- Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
- NCT number
- NCT02980874
- Phases
- PHASE3
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
- Lead sponsor
- Clearside Biomedical, Inc.
- Results first posted
- 2021-04-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02980874?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02980874-sae